These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34132615)

  • 21. SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease.
    Wang P; Liu L; Nair MS; Yin MT; Luo Y; Wang Q; Yuan T; Mori K; Solis AG; Yamashita M; Garg A; Purpura LJ; Laracy JC; Yu J; Joshua-Tor L; Sodroski J; Huang Y; Ho DD
    Emerg Microbes Infect; 2020 Dec; 9(1):2091-2093. PubMed ID: 32930052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants.
    Morinaga Y; Tani H; Terasaki Y; Nomura S; Kawasuji H; Shimada T; Igarashi E; Saga Y; Yoshida Y; Yasukochi R; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Fujimura T; Ishida Y; Oishi K; Yamamoto Y
    Microbiol Spectr; 2021 Dec; 9(3):e0056021. PubMed ID: 34851163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
    Moyo-Gwete T; Madzivhandila M; Makhado Z; Ayres F; Mhlanga D; Oosthuysen B; Lambson BE; Kgagudi P; Tegally H; Iranzadeh A; Doolabh D; Tyers L; Chinhoyi LR; Mennen M; Skelem S; Marais G; Wibmer CK; Bhiman JN; Ueckermann V; Rossouw T; Boswell M; de Oliveira T; Williamson C; Burgers WA; Ntusi N; Morris L; Moore PL
    N Engl J Med; 2021 Jun; 384(22):2161-2163. PubMed ID: 33826816
    [No Abstract]   [Full Text] [Related]  

  • 24. Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination.
    Rosati M; Terpos E; Agarwal M; Karalis V; Bear J; Burns R; Hu X; Papademetriou D; Ntanasis-Stathopoulos I; Trougakos IP; Dimopoulos MA; Pavlakis GN; Felber BK
    Am J Hematol; 2022 Jan; 97(1):E3-E7. PubMed ID: 34674297
    [No Abstract]   [Full Text] [Related]  

  • 25. Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals.
    Stelitano D; Weisberg SP; Goldklang MP; Zhu Y; Bovier FT; Kalantarov GF; Greco G; Decimo D; Franci G; Cennamo M; Portella G; Galdiero M; Mathieu C; Horvat B; Trakht IN; Moscona A; Whitt MA; Porotto M
    mSphere; 2021 Aug; 6(4):e0057121. PubMed ID: 34319126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.
    Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Holzer B; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Hartmann B; Tancevski I; Weiss G; Binder CJ; Anliker M; Griesmacher A; Hoermann G
    Clin Chem Lab Med; 2021 Jul; 59(8):1453-1462. PubMed ID: 33837679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies.
    Hu J; Peng P; Wang K; Fang L; Luo FY; Jin AS; Liu BZ; Tang N; Huang AL
    Cell Mol Immunol; 2021 Apr; 18(4):1061-1063. PubMed ID: 33633321
    [No Abstract]   [Full Text] [Related]  

  • 28. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
    McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A flow cytometry-based assay to measure neutralizing antibodies against SARS-CoV-2 virus.
    Pscheidt VM; de Souza PO; Fazolo T; Modena JLP; Simeoni C; Teixeira D; Silva NB; Dos Santos KB; Júnior LR; Bonorino C
    Cytometry A; 2024 Jun; 105(6):446-457. PubMed ID: 38624015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2.
    Arora P; Kempf A; Nehlmeier I; Graichen L; Winkler MS; Lier M; Schulz S; Jäck HM; Pöhlmann S; Hoffmann M
    Cell Mol Immunol; 2022 Mar; 19(3):449-452. PubMed ID: 34983951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2.
    Bahnan W; Wrighton S; Sundwall M; Bläckberg A; Larsson O; Höglund U; Khakzad H; Godzwon M; Walle M; Elder E; Strand AS; Happonen L; André O; Ahnlide JK; Hellmark T; Wendel-Hansen V; Wallin RP; Malmstöm J; Malmström L; Ohlin M; Rasmussen M; Nordenfelt P
    Front Immunol; 2021; 12():808932. PubMed ID: 35095897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays.
    Virtanen J; Uusitalo R; Korhonen EM; Aaltonen K; Smura T; Kuivanen S; Pakkanen SH; Mero S; Patjas A; Riekkinen M; Kantele A; Nurmi V; Hedman K; Hepojoki J; Sironen T; Huhtamo E; Vapalahti O
    Viruses; 2021 May; 13(6):. PubMed ID: 34073577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies.
    Chapman AP; Tang X; Lee JR; Chida A; Mercer K; Wharton RE; Kainulainen M; Harcourt JL; Martines RB; Schroeder M; Zhao L; Bryksin A; Zhou B; Bergeron E; Bollweg BC; Tamin A; Thornburg N; Wentworth DE; Petway D; Bagarozzi DA; Finn MG; Goldstein JM
    Sci Rep; 2021 May; 11(1):9682. PubMed ID: 33958613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serological response in health care workers after a single dose of SARS-CoV-2 vaccine using six automated SARS-CoV-2 antibody assays.
    Cuykx M; Mortelé O; Jansens H; Schouwers S; Meskal A; Hoffbauer I; Peeters B
    Diagn Microbiol Infect Dis; 2021 Oct; 101(2):115486. PubMed ID: 34332306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2.
    Deshpande GR; Kaduskar O; Deshpande K; Bhatt V; Yadav P; Gurav Y; Potdar V; Khutwad K; Vidhate S; Salunke A; Patil C; Shingade S; Jarande K; Tilekar B; Salvi P; Patsuthe S; Dange V; Kumar S; Gurav S; Chate S; Abraham P; Sapkal G
    Int J Infect Dis; 2021 Nov; 112():103-110. PubMed ID: 34543771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.
    Valcourt EJ; Manguiat K; Robinson A; Lin YC; Abe KT; Mubareka S; Shigayeva A; Zhong Z; Girardin RC; DuPuis A; Payne A; McDonough K; Wang Z; Gasser R; Laumaea A; Benlarbi M; Richard J; Prévost J; Anand SP; Dimitrova K; Phillipson C; McGeer A; Gingras AC; Liang C; Petric M; Sekirov I; Morshed M; Finzi A; Drebot M; Wood H
    Microbiol Spectr; 2021 Dec; 9(3):e0088621. PubMed ID: 34787495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA.
    Zeng W; Ma H; Ding C; Yang Y; Sun Y; Huang X; He W; Xiang Y; Gao Y; Jin T
    Signal Transduct Target Ther; 2021 Jan; 6(1):35. PubMed ID: 33514692
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma.
    von Rhein C; Scholz T; Henss L; Kronstein-Wiedemann R; Schwarz T; Rodionov RN; Corman VM; Tonn T; Schnierle BS
    J Virol Methods; 2021 Feb; 288():114031. PubMed ID: 33275926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A SARS-CoV-2 Neutralization Assay Using Single Molecule Arrays.
    Gilboa T; Cohen L; Cheng CA; Lazarovits R; Uwamanzu-Nna A; Han I; Griswold K; Barry N; Thompson DB; Kohman RE; Woolley AE; Karlson EW; Walt DR
    Angew Chem Int Ed Engl; 2021 Dec; 60(49):25966-25972. PubMed ID: 34534408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2.
    Ahn TS; Han B; Krogstad P; Bun C; Kohn LA; Garcia-Lloret MI; Damoiseaux R; Butte MJ
    J Allergy Clin Immunol; 2021 Mar; 147(3):876-877. PubMed ID: 33358557
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.